Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by
the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the …

Simple Summary In Chronic Myeloid Leukemia (CML), intra-clonal heterogeneity is a major
factor in the response to tyrosine kinase inhibitors and in leukemia stem cell persistence …

Background There is strong evidence that disease progression, drug response and overall
clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but …

The epigenetic impact of DNA methylation in chronic myelogenous leukemia (CML) is not
completely understood. To elucidate its role we analyzed 120 patients with CML for …

Epigenetic regulation has been thoroughly investigated in recent years and has emerged as
an important aspect of chronic lymphocytic leukemia (CLL) biology. Characteristic aberrant …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the
genetic translocation t (9; 22)(q34; q11. 2) encoding for the BCR-ABL fusion oncogene …

Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies
have been dominated by the primary focus of understanding promoter hypermethylation …

Chronic myelogenous leukemia (CML) has a typical progressive course with transition from
a chronic phase to a terminal blast crisis phase. The mechanisms that lead to disease …

Acute myeloid leukemia (AML) is a heterogeneous disease that is characterized by distinct
cytogenetic or genetic abnormalities. Recent discoveries in cancer epigenetics …

Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic
myeloid leukemia (CML) will display residual disease that can become resistant to …